Ibrutinib in previously treated Waldenström's macroglobulinemia

New England Journal of Medicine

Volumn 372, Issue 15, 2015, Pages 1430-1440

  Treon, Steven P ^a,b   Tripsas, Christina K ^a   Meid, Kirsten ^a   Warren, Diane ^a   Varma, Gaurav ^g   Green, Rebecca ^f   Argyropoulos, Kimon V ^f   Yang, Guang ^a,b   Cao, Yang ^a,b   Xu, Lian ^a   Patterson, Christopher J ^a   Rodig, Scott ^a,b,c   Zehnder, James L ^g   Aster, Jon C ^b,c   Harris, Nancy Lee ^b,d   Kanan, Sandra ^a   Ghobrial, Irene ^a,b   Castillo, Jorge J ^a,b   Laubach, Jacob P ^a,b   Hunter, Zachary R ^a,e   Salman, Zeena ^h   Li, Jianling ^h   Cheng, Mei ^h   Clow, Fong ^h   Graef, Thorsten ^h   Palomba, M Lia ^f   Advani, Ranjana H ^g   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FISH OIL; HEMOGLOBIN; IBRUTINIB; IMMUNOGLOBULIN M; MYELOID DIFFERENTIATION FACTOR 88; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CXCR4 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW; CLINICAL TRIAL; CXCR4 GENE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; EPISTAXIS; FEMALE; GENE; GENE MUTATION; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYD88 GENE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; WALDENSTROEM MACROGLOBULINEMIA; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; SURVIVAL RATE; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN M; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, CXCR4; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84927155030     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1501548     Document Type: Article

References (34)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5.
2. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012;367:826-33.
3. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123:1637-46.
4. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013;122:1222-32.
5. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.
6. Dotta L, Tassone L, Badolato R. Clinical and genetic features of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. Curr Mol Med 2011;11:317-25.
7. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123:2791-6.
8. Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia 2015;29:169-76.
9. Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signaling in Waldenstrom macroglobulinemia cells. Br J Haematol 2015;168:701-7.
10. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 2014;123:4120-31.
11. Anderson KC, Alsina M, Bensinger W, et al. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw 2012;10:1211-9.
12. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116-20.
13. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051-8.
14. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia 2014;28:1698-704.
15. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113:4163-70.
16. Ngo HT, Leleu X, Lee J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008;112:150-8.
17. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
18. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
19. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-4.
20. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014;28:2188-96.
21. Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia 2013;27:1722-8.
22. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504-11.
23. Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009;?114:?2375-85.
24. Dimopoulos M, Kastritis E, Owen R, et al. Treatment recommendations for patients with Waldenström's macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014;124:1404-11.
25. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-33.
26. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-5.
27. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-12.
28. Treon SP, Tripsas CK, Ioakimidis L, et al. Prospective, multicenter study of the MTOR-inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia. Presented at the 53rd ASH Annual Meeting and Exposition, San Diego, December 10-13, 2011. abstract (https://ash.confex.com/ash/2011/webprogram/Paper44858.html).
29. Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Novak AJ, Ansell SM. Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia. Blood 2014;123:1055-8.
30. Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C, Uckun FM. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 2001;276:31216-28.
31. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012;5:CD002827.
32. Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80:2217-25.
33. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011;118:4957-62.
34. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23.